title: [A combination study of S-1 and docetaxel in patients with head and neck cancer].
abstract: We determined the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of drug sequence on toxicities of the combination of S-1 and docetaxel for head and neck cancers. S-1 was administered at the full dose of 80 mg/m2 for two weeks and docetaxel on day 1 according to the following dose escalation schedule: level 1: 40 mg/m2, level 2: 50 mg/m2, and level 3: 60 mg/m2. DLT was observed in two cases of level 3. Although grade 3 leukopenia was observed in level 3, all of the toxicities were not severe. Recommended doses for the next phase evaluation were determined to be 80 mg/m2 of S-1 and 50 mg/m2 of docetaxel. Oral S-1 combination with docetaxel is a feasible and promising combination regimen that is appropriate for an outpatient setting.
authors.affiliation: Dept. of Otolaryngology, Tokyo Medical University, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ito
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Ryoji
authors.initials: R
authors.lastname: Tokashiki
authors.forename: Akira
authors.initials: A
authors.lastname: Shimizu
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hiramatsu
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Tsukahara
authors.forename: Nobutoshi
authors.initials: N
authors.lastname: Funato
mesh_terms: D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D020714:Maximum Tolerated Dose; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid